--- title: "Prothena | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 1.01 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295145313.md" datetime: "2026-08-06T21:18:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295145313.md) - [en](https://longbridge.com/en/news/295145313.md) - [zh-HK](https://longbridge.com/zh-HK/news/295145313.md) generator: "portal-rs" --- # Prothena | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 1.01 M Revenue: As of FY2026 Q2, the actual value is USD 1.01 M, beating the estimate of USD 421.67 K. EPS: As of FY2026 Q2, the actual value is USD -0.36, beating the estimate of USD -0.39. EBIT: As of FY2026 Q2, the actual value is USD -18.58 M. ### Financial Performance Summary for Prothena Corporation plc #### Net Income (Loss) Prothena Corporation plc reported a net loss of - $18.6 million for the second quarter of 2026, compared to a net loss of - $125.8 million for the same period in 2025. For the first six months of 2026, the company reported a net income of $14.1 million, a significant improvement from a net loss of - $186.0 million for the first six months of 2025. #### Total Revenue Total revenue for the second quarter of 2026 was $1.0 million, down from $4.4 million in the second quarter of 2025. For the first six months of 2026, total revenue was $52.1 million, a substantial increase from $7.2 million in the first six months of 2025. Revenue for the first six months of 2026 was primarily driven by a $50.0 million milestone payment from Novo Nordisk related to the ongoing Phase 3 clinical trial for coramitug, as well as collaboration revenue from Bristol Myers Squibb for the partial performance of the PRX019 Phase 1 clinical trial obligation. Revenue for both the second quarter and first six months of 2025 primarily stemmed from collaboration revenue from Bristol Myers Squibb related to the PRX019 Phase 1 clinical trial obligation. #### Operating Expenses - **Research and Development (R&D) Expenses**: R&D expenses totaled $8.8 million for the second quarter of 2026, a decrease from $40.5 million in the second quarter of 2025. For the first six months of 2026, R&D expenses were $21.4 million, down from $91.3 million in the comparable period of 2025. This decrease was primarily attributed to lower clinical trial expenses, personnel expenses, consulting expenses, and manufacturing expenses. Non-cash share-based compensation expense included in R&D was $1.7 million for Q2 2026 and $3.7 million for H1 2026, compared to $4.7 million for Q2 2025 and $9.5 million for H1 2025. - **General and Administrative (G&A) Expenses**: G&A expenses were $10.9 million for the second quarter of 2026, compared to $15.9 million for the second quarter of 2025. For the first six months of 2026, G&A expenses amounted to $23.6 million, down from $33.5 million in the first six months of 2025. This reduction was mainly due to lower consulting and personnel expenses. Non-cash share-based compensation expense included in G&A was $4.5 million for Q2 2026 and $9.4 million for H1 2026, compared to $5.7 million for Q2 2025 and $11.8 million for H1 2025. - **Restructuring Costs**: Prothena Corporation plc recorded restructuring expenses of $2.4 million for the second quarter of 2026, compared to $32.6 million for the same period in 2025. For the first six months of 2026, the company reported an aggregate restructuring credit of - $1.8 million, compared to expenses of $32.6 million for the first six months of 2025. Restructuring expenses included non-cash share-based compensation expense of $1.7 million for both Q2 and H1 2026, compared to $2.1 million for both Q2 and H1 2025. #### Total Non-Cash Share-Based Compensation Expense Total non-cash share-based compensation expense was $7.9 million for the second quarter of 2026 and $14.8 million for the first six months of 2026, compared to $12.4 million and $23.4 million for the respective periods in 2025. #### Cash Flow and Cash Position Net cash used in operating and investing activities was - $25.7 million in the second quarter of 2026. For the first six months of 2026, net cash provided by operating and investing activities was $3.2 million. As of June 30, 2026, Prothena Corporation plc had $289.1 million in cash, cash equivalents, and restricted cash, with no debt. #### Share Repurchase Program Prothena Corporation plc repurchased 1,454,898 ordinary shares in the second quarter of 2026. In total, the company repurchased 2,243,888 ordinary shares for $22.3 million during the first half of 2026 under its up to $100.0 million share repurchase program, which expires on December 31, 2026. #### Operational Metrics & Partnered Programs Prothena Corporation plc’s partnered programs have the potential to generate up to approximately $3 billion in aggregate future milestone payments, plus potential royalties. Roche has stated that prasinezumab, a Parkinson’s disease treatment, has peak sales potential greater than $3.5 billion (unadjusted) and could be the first disease-modifying treatment for Parkinson’s disease. Prothena Corporation plc could also earn a $55 million clinical milestone payment in 2026 if Bristol Myers Squibb advances the PRX019 program for neurodegenerative diseases. #### 2026 Financial Guidance Prothena Corporation plc anticipates full-year 2026 net cash used in operating and investing activities to be between - $18 million and - $23 million. The company expects to end 2026 with approximately $259 million (midpoint) in cash, cash equivalents, and restricted cash, which is a decrease of $14 million from prior guidance due to cash utilized for share repurchases. This guidance is based on an estimated net loss of - $25 million to - $30 million, including an estimated $26 million of non-cash share-based compensation expense, and excludes the potential $55 million clinical milestone payment for PRX019 or additional share repurchases. ### Related Stocks - [PRTA.US](https://longbridge.com/en/quote/PRTA.US.md) ## Related News & Research - [Prothena files initial beneficial ownership statement for Todd W. Fennell](https://longbridge.com/en/news/296266092.md) - [Major Insider Move Signals Growing Confidence in Prothena Shares](https://longbridge.com/en/news/296664234.md) - [Prothena 10% owner William P. Scully buys $439,430 of common shares](https://longbridge.com/en/news/296644095.md) - [Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split](https://longbridge.com/en/news/296471274.md) - [Prothena 10% owner William P. Scully buys $293,052 of common shares](https://longbridge.com/en/news/295440858.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**